Edition:
India

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

2.96USD
24 May 2019
Change (% chg)

$-0.05 (-1.66%)
Prev Close
$3.01
Open
$3.02
Day's High
$3.02
Day's Low
$2.95
Volume
1,485
Avg. Vol
6,186
52-wk High
$11.65
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Reports Q3 Loss Per Share Of $0.36 From Continuing Operations
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.36 FROM CONTINUING OPERATIONS.CALADRIUS BIOSCIENCES - AS OF SEPT 30 CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $46.1 MILLION VERSUS $60.1 MILLION AS OF DEC 31, 2017.CALADRIUS BIOSCIENCES - EXPECTS CASH BALANCE WILL ALLOW CO TO FUND CURRENT BUSINESS PLAN BEYOND 2019.  Full Article

Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations
Friday, 11 May 2018 

May 10 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52 FROM CONTINUING OPERATIONS.  Full Article

Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops
Friday, 23 Mar 2018 

March 22 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.40 FROM CONTINUING OPERATIONS.CALADRIUS - ‍AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $60.1 MILLION VERSUS $7.1 MILLION AS OF DEC 31, 2016​.CALADRIUS BIOSCIENCES - ‍CONFIDENT THAT CASH BALANCES, ADDITIONAL GRANT FUNDING WILL ALLOW IT TO FUND ITS CURRENT BUSINESS PLAN BEYOND 2019​.  Full Article

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.  Full Article

Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co
Friday, 9 Feb 2018 

Feb 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION.  Full Article

Caladrius Biosciences reports 2017 third quarter results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article

Caladrius Biosciences files for resale of co's common stock‍​ by the selling stockholders
Wednesday, 6 Sep 2017 

Sept 6 (Reuters) - Caladrius Biosciences Inc :Files for resale of up to 932,204 shares of Co's common stock‍​ by the selling stockholders - SEC filing.  Full Article

Caladrius Biosciences Q2 loss per share $0.22 from continuing operations
Friday, 11 Aug 2017 

Aug 10 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 second quarter results.Q2 loss per share $0.22 from continuing operations.  Full Article

Caladrius Biosciences says 50 pct of subjects have been treated in the phase 2 clinical trial of CLBS03
Wednesday, 19 Jul 2017 

July 19 (Reuters) - Caladrius Biosciences Inc ::Caladrius Biosciences announces that 50 pct of subjects have been treated in the phase 2 clinical trial of clbs03 for type 1 diabetes.Caladrius - interim analysis of early therapeutic effect to occur after 6 month post-treatment follow-up visit,results in late 2017/early 2018.  Full Article